My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 384

    1.

    Media influence on Herceptin subsidization in Australia: application of the rule of rescue?

    Mackenzie R, Chapman S, Salkeld G, Holding S.

    J R Soc Med. 2008 Jun;101(6):305-12.PMID: 18515778 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.

    Wilson PM, Booth AM, Eastwood A, Watt IS.

    J R Soc Med. 2008 Mar;101(3):125-32.PMID: 18344469 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.

    McKeage K, Lyseng-Williamson KA.

    Pharmacoeconomics. 2008;26(8):699-719. Review.PMID: 18620462 [PubMed - indexed for MEDLINE]Related articles

    4.

    PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?

    Rosevear M.

    N Z Med J. 2006 Jun 2;119(1235):U2014.PMID: 16751832 [PubMed - indexed for MEDLINE]Related articles

    5.

    External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

    Booth CM, Dranitsaris G, Gainford MC, Berry S, Fralick M, Fralick J, Sue J, Clemons M.

    BMC Cancer. 2007 Jun 28;7:110. Review.PMID: 17598896 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.

    Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D.

    Health Policy. 2008 Aug;87(2):146-59. Epub 2008 Mar 4.PMID: 18164510 [PubMed - indexed for MEDLINE]Related articles

    7.

    Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.

    Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF.

    Int J Technol Assess Health Care. 2005 Winter;21(1):132-7.PMID: 15736525 [PubMed - indexed for MEDLINE]Related articles

    8.

    Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program.

    Pearson SA, Ringland CL, Ward RL.

    J Clin Oncol. 2007 Aug 20;25(24):3688-93.PMID: 17704417 [PubMed - indexed for MEDLINE]Related articles

    9.

    How much will Herceptin really cost?

    Barrett A, Roques T, Small M, Smith RD.

    BMJ. 2006 Nov 25;333(7578):1118-20. Review. No abstract available. PMID: 17124225 [PubMed - indexed for MEDLINE]Related articles

    10.

    Mixed messages and a missed opportunity: Australian news media coverage of Clare Oliver's campaign against solaria.

    MacKenzie R, Imison M, Chapman S, Holding S.

    Med J Aust. 2008 Oct 6;189(7):371-4.PMID: 18837679 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial.

    Neyt M, Albrecht J, Cocquyt V.

    Ann Oncol. 2006 Mar;17(3):381-90. Epub 2005 Nov 30.PMID: 16319089 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.

    Breast Cancer Advocacy Coalition, Burgess EP.

    N Z Med J. 2006 Jul 7;119(1237):U2065; author reply U2065. No abstract available. PMID: 16862207 [PubMed - indexed for MEDLINE]Related articles

    13.

    How much will Herceptin really cost? Balancing local and national priorities is not new.

    Dillon A, Littlejohns P.

    BMJ. 2006 Dec 9;333(7580):1219; discussion 1219-20. No abstract available. PMID: 17158393 [PubMed - indexed for MEDLINE]Related articles

    14.

    Impact of news of celebrity illness on breast cancer screening: Kylie Minogue's breast cancer diagnosis.

    Chapman S, McLeod K, Wakefield M, Holding S.

    Med J Aust. 2005 Sep 5;183(5):247-50.PMID: 16138798 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.

    Kondo M, Toi M.

    Expert Rev Anticancer Ther. 2006 Feb;6(2):197-204. Review.PMID: 16445372 [PubMed - indexed for MEDLINE]Related articles

    16.

    Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?

    Hillner BE, Smith TJ.

    J Clin Oncol. 2007 Feb 20;25(6):611-3. No abstract available. PMID: 17308264 [PubMed - indexed for MEDLINE]Related articles

    17.

    [Reflexion on innovation diffusion factors: the case of Herceptin]

    Buron C, Doz M, Salomon AV, Couturier J, Beuzeboc P, Livartowski A.

    Bull Cancer. 2007 Mar 1;94(3):297-306. French. PMID: 17371772 [PubMed - indexed for MEDLINE]Related articles

    18.

    PHARMAC responds on Herceptin assumptions and decisions.

    Metcalfe S, Evans J.

    N Z Med J. 2007 Aug 24;120(1260):U2692. No abstract available. PMID: 17726504 [PubMed - indexed for MEDLINE]Related articles

    19.

    PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.

    Isaacs RJ, Frampton CM, Kuper-Hommel MJ.

    N Z Med J. 2007 Aug 10;120(1259):U2676. No abstract available. PMID: 17721579 [PubMed - indexed for MEDLINE]Related articles

    20.

    It's money that matters: the financial context of ethical decision-making in modern biomedicine.

    Hedgecoe AM.

    Sociol Health Illn. 2006 Sep;28(6):768-84.PMID: 17184417 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity